TScan Therapeutics (TCRX) Investor Presentation - Slideshow

• Endpoints TScan Therapeutics, Inc. 30 1 2 3 Archival sample <6mo OR fresh biopsy Targets TSC-200 TSC-203 TSC-202 TSC-204 A02:01A01:01A03:01B07:02C07:02 TSC-201 A24:02 TSC-205 HPV16 Target-202 Target-201 PRAME MAGE-A1 Target-205 10+ TCRs in the clinic by the end of 2024 the early stages of building the ImmunoBank 1 2 3 4 5 6 7 8 9 0 20 40 60 80 100 Eligible patients (%) Melanoma -single NSCLC-single TScan Therapeutics, Inc. 33 TCR-T uniquely addresses myeloid leukemias Not addressable by CAR-T therap ...